Crispr Net Debt vs Other Current Assets Analysis

CRSP Stock

USD 55.21 1.05 1.87%

Crispr Therapeutics financial indicator trend analysis is way more than just evaluating Crispr Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Crispr Therapeutics is a good investment. Please check the relationship between Crispr Therapeutics Net Debt and its Other Current Assets accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Crispr Therapeutics AG. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

Net Debt vs Other Current Assets

Net Debt vs Other Current Assets Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Crispr Therapeutics Net Debt account and Other Current Assets. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Crispr Therapeutics' Net Debt and Other Current Assets is -0.27. Overlapping area represents the amount of variation of Net Debt that can explain the historical movement of Other Current Assets in the same time period over historical financial statements of Crispr Therapeutics AG, assuming nothing else is changed. The correlation between historical values of Crispr Therapeutics' Net Debt and Other Current Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Debt of Crispr Therapeutics AG are associated (or correlated) with its Other Current Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Current Assets has no effect on the direction of Net Debt i.e., Crispr Therapeutics' Net Debt and Other Current Assets go up and down completely randomly.

Correlation Coefficient

-0.27

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Net Debt

The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.

Other Current Assets

Assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories.

Most indicators from Crispr Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Crispr Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Crispr Therapeutics AG. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

As of 08/01/2025, Tax Provision is likely to grow to about 3.8 M, while Selling General Administrative is likely to drop slightly above 64 M.

	2022	2023	2025 (projected)
Total Operating Expenses	563.3M	462.3M	304.1M
Cost Of Revenue	110.3M	130.3M	114.1M

Total Operating Expenses Cost Of Revenue

Crispr Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Short Long Term Debt	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock
Total Assets		0.98	0.99	1.0	-0.12	0.96	-0.37	-0.73	0.82	0.63	0.95	0.87	0.96	1.0	0.4	0.92	0.95	0.84	0.84	0.92	0.92	0.41	1.0	-0.54	-0.92	0.92
Other Current Liab	0.98		0.97	0.98	-0.23	0.93	-0.39	-0.64	0.76	0.63	0.92	0.83	0.93	0.98	0.31	0.84	0.92	0.8	0.85	0.88	0.89	0.34	0.98	-0.61	-0.84	0.84
Total Current Liabilities	0.99	0.97		0.99	-0.1	0.94	-0.4	-0.71	0.85	0.65	0.94	0.83	0.94	0.98	0.41	0.92	0.93	0.82	0.88	0.91	0.92	0.33	0.99	-0.5	-0.91	0.93
Total Stockholder Equity	1.0	0.98	0.99		-0.16	0.96	-0.4	-0.72	0.81	0.65	0.94	0.87	0.96	1.0	0.39	0.92	0.95	0.8	0.83	0.92	0.9	0.41	1.0	-0.56	-0.91	0.92
Other Liab	-0.12	-0.23	-0.1	-0.16		-0.18	-0.22	0.14	-0.1	0.14	-0.18	-0.14	-0.13	-0.11	-0.11	0.11	-0.23	0.19	-0.06	-0.17	0.1	-0.08	-0.11	0.43	0.0	0.11
Net Tangible Assets	0.96	0.93	0.94	0.96	-0.18		-0.32	-0.83	0.77	0.62	0.9	0.96	0.99	0.96	0.36	0.89	0.92	0.79	0.79	0.98	0.87	0.56	0.96	-0.58	-0.95	0.9
Net Debt	-0.37	-0.39	-0.4	-0.4	-0.22	-0.32		-0.03	-0.03	-0.93	-0.09	-0.25	-0.36	-0.43	0.14	-0.48	-0.32	-0.06	-0.27	-0.22	-0.18	0.14	-0.42	0.42	0.29	-0.47
Retained Earnings	-0.73	-0.64	-0.71	-0.72	0.14	-0.83	-0.03		-0.72	-0.28	-0.73	-0.87	-0.8	-0.71	-0.47	-0.74	-0.77	-0.68	-0.5	-0.91	-0.72	-0.79	-0.72	0.45	0.89	-0.76
Accounts Payable	0.82	0.76	0.85	0.81	-0.1	0.77	-0.03	-0.72		0.29	0.89	0.62	0.74	0.78	0.77	0.76	0.79	0.81	0.72	0.8	0.86	0.23	0.81	-0.16	-0.82	0.77
Cash	0.63	0.63	0.65	0.65	0.14	0.62	-0.93	-0.28	0.29		0.37	0.56	0.65	0.67	0.01	0.69	0.57	0.33	0.49	0.54	0.45	0.09	0.67	-0.56	-0.59	0.7
Non Current Assets Total	0.95	0.92	0.94	0.94	-0.18	0.9	-0.09	-0.73	0.89	0.37		0.8	0.87	0.92	0.46	0.84	0.91	0.88	0.86	0.88	0.94	0.41	0.93	-0.41	-0.87	0.84
Non Currrent Assets Other	0.87	0.83	0.83	0.87	-0.14	0.96	-0.25	-0.87	0.62	0.56	0.8		0.96	0.88	0.23	0.82	0.84	0.72	0.67	0.96	0.79	0.73	0.87	-0.59	-0.91	0.84
Other Assets	0.96	0.93	0.94	0.96	-0.13	0.99	-0.36	-0.8	0.74	0.65	0.87	0.96		0.96	0.33	0.89	0.9	0.78	0.79	0.97	0.87	0.53	0.96	-0.55	-0.94	0.9
Cash And Short Term Investments	1.0	0.98	0.98	1.0	-0.11	0.96	-0.43	-0.71	0.78	0.67	0.92	0.88	0.96		0.34	0.93	0.94	0.81	0.84	0.92	0.91	0.42	1.0	-0.57	-0.91	0.93
Net Receivables	0.4	0.31	0.41	0.39	-0.11	0.36	0.14	-0.47	0.77	0.01	0.46	0.23	0.33	0.34		0.36	0.41	0.45	0.16	0.42	0.45	0.07	0.39	0.16	-0.46	0.37
Common Stock Total Equity	0.92	0.84	0.92	0.92	0.11	0.89	-0.48	-0.74	0.76	0.69	0.84	0.82	0.89	0.93	0.36		0.89	0.76	0.76	0.88	0.85	0.46	0.93	-0.48	-0.94	1.0
Common Stock Shares Outstanding	0.95	0.92	0.93	0.95	-0.23	0.92	-0.32	-0.77	0.79	0.57	0.91	0.84	0.9	0.94	0.41	0.89		0.77	0.79	0.91	0.86	0.47	0.94	-0.67	-0.92	0.89
Non Current Liabilities Total	0.84	0.8	0.82	0.8	0.19	0.79	-0.06	-0.68	0.81	0.33	0.88	0.72	0.78	0.81	0.45	0.76	0.77		0.73	0.79	0.98	0.43	0.82	-0.26	-0.82	0.76
Other Current Assets	0.84	0.85	0.88	0.83	-0.06	0.79	-0.27	-0.5	0.72	0.49	0.86	0.67	0.79	0.84	0.16	0.76	0.79	0.73		0.74	0.81	0.09	0.83	-0.38	-0.74	0.76
Other Stockholder Equity	0.92	0.88	0.91	0.92	-0.17	0.98	-0.22	-0.91	0.8	0.54	0.88	0.96	0.97	0.92	0.42	0.88	0.91	0.79	0.74		0.86	0.63	0.92	-0.55	-0.97	0.9
Total Liab	0.92	0.89	0.92	0.9	0.1	0.87	-0.18	-0.72	0.86	0.45	0.94	0.79	0.87	0.91	0.45	0.85	0.86	0.98	0.81	0.86		0.41	0.91	-0.36	-0.88	0.85
Short Long Term Debt	0.41	0.34	0.33	0.41	-0.08	0.56	0.14	-0.79	0.23	0.09	0.41	0.73	0.53	0.42	0.07	0.46	0.47	0.43	0.09	0.63	0.41		0.41	-0.47	-0.59	0.46
Total Current Assets	1.0	0.98	0.99	1.0	-0.11	0.96	-0.42	-0.72	0.81	0.67	0.93	0.87	0.96	1.0	0.39	0.93	0.94	0.82	0.83	0.92	0.91	0.41		-0.55	-0.91	0.93
Short Term Debt	-0.54	-0.61	-0.5	-0.56	0.43	-0.58	0.42	0.45	-0.16	-0.56	-0.41	-0.59	-0.55	-0.57	0.16	-0.48	-0.67	-0.26	-0.38	-0.55	-0.36	-0.47	-0.55		0.5	-0.47
Intangible Assets	-0.92	-0.84	-0.91	-0.91	0.0	-0.95	0.29	0.89	-0.82	-0.59	-0.87	-0.91	-0.94	-0.91	-0.46	-0.94	-0.92	-0.82	-0.74	-0.97	-0.88	-0.59	-0.91	0.5		-0.95
Common Stock	0.92	0.84	0.93	0.92	0.11	0.9	-0.47	-0.76	0.77	0.7	0.84	0.84	0.9	0.93	0.37	1.0	0.89	0.76	0.76	0.9	0.85	0.46	0.93	-0.47	-0.95

Click cells to compare fundamentals

Crispr Therapeutics Account Relationship Matchups

Crispr Therapeutics fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	1.8B	2.8B	2.2B	2.2B	2.2B	1.4B
Other Current Liab	49.6M	79.0M	61.9M	50.5M	51.9M	33.6M
Total Current Liabilities	94.3M	119.9M	121.1M	108.8M	87.8M	66.5M
Total Stockholder Equity	1.7B	2.4B	1.9B	1.9B	1.9B	1.1B
Other Liab	26.2M	19.4M	19.7M	18.3M	16.5M	15.6M
Net Tangible Assets	939.2M	1.7B	2.4B	1.9B	2.2B	2.3B
Net Debt	(1.1B)	(698.0M)	32.1M	(150.8M)	(74.6M)	(78.3M)
Retained Earnings	(573.6M)	(195.9M)	(846.1M)	(999.7M)	(1.4B)	(1.3B)
Accounts Payable	9.1M	14.8M	27.4M	38.1M	14.7M	12.3M
Cash	1.2B	923.0M	211.9M	389.5M	298.3M	510.4M
Non Current Assets Total	111.3M	334.4M	390.0M	321.5M	304.9M	161.5M
Non Currrent Assets Other	18.1M	22.2M	16.3M	13.6M	27.3M	28.7M
Other Assets	6.1M	18.1M	22.2M	16.3M	18.7M	19.7M
Cash And Short Term Investments	1.7B	2.4B	1.8B	1.7B	1.9B	1.2B
Net Receivables	144K	305K	11.2M	200M	25M	24.6M
Common Stock Total Equity	1.8M	2.3M	2.4M	2.4M	2.8M	1.6M
Common Stock Shares Outstanding	65.9M	80.4M	77.7M	79.2M	84.4M	60.3M
Liabilities And Stockholders Equity	1.8B	2.8B	2.2B	2.2B	2.2B	1.4B
Non Current Liabilities Total	69.5M	232.5M	246.5M	238.0M	222.2M	149.2M
Other Current Assets	15.4M	29.7M	37.7M	14.4M	8.3M	13.0M
Other Stockholder Equity	2.2B	2.6B	2.7B	2.9B	3.3B	3.5B
Total Liab	163.7M	352.4M	367.6M	346.8M	310.0M	215.7M
Total Current Assets	1.7B	2.4B	1.9B	1.9B	1.9B	1.2B
Accumulated Other Comprehensive Income	(83K)	(5.1M)	(15.6M)	1.9M	1.8M	1.9M
Short Term Debt	22.7M	24.3M	31.7M	43.6M	17.3M	27.1M
Intangible Assets	180K	125K	71K	16K	14.4K	13.7K
Common Stock	2.3M	2.4M	2.4M	2.5M	2.7M	1.8M
Short Long Term Debt Total	61.4M	225.0M	244.0M	238.6M	223.7M	170.3M
Property Plant And Equipment Net	93.0M	312.0M	320.6M	305.9M	277.6M	158.6M
Capital Surpluse	1.2B	2.2B	2.6B	2.7B	3.1B	3.3B
Property Plant And Equipment Gross	93.0M	137.6M	163.6M	359.4M	349.8M	367.3M
Property Plant Equipment	72.8M	42.2M	137.6M	163.6M	188.2M	197.6M
Current Deferred Revenue	2.3M	1.0M	12.3M	4.1M	3.8M	3.7M
Retained Earnings Total Equity	(224.7M)	(573.6M)	(195.9M)	(846.1M)	(761.5M)	(723.4M)
Non Current Liabilities Other	69.5M	232.5M	6.0M	958K	3.4M	3.3M
Net Invested Capital	1.7B	2.4B	1.9B	1.9B	1.9B	1.6B

Additional Tools for Crispr Stock Analysis

When running Crispr Therapeutics' price analysis, check to measure Crispr Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crispr Therapeutics is operating at the current time. Most of Crispr Therapeutics' value examination focuses on studying past and present price action to predict the probability of Crispr Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crispr Therapeutics' price. Additionally, you may evaluate how the addition of Crispr Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC

Crispr Net Debt vs Other Current Assets Analysis

Net Debt vs Other Current Assets

Net Debt vs Other Current Assets Correlation Analysis

Correlation Coefficient

Net Debt

Other Current Assets

Crispr Therapeutics fundamental ratios Correlations

Crispr Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Crispr Therapeutics fundamental ratios Accounts

Additional Tools for Crispr Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Cash And Short Term Investments

Intangible Assets	- 0.97	Other Stockholder Equity
Common Stock	- 0.95	Intangible Assets
Intangible Assets	- 0.95	Net Tangible Assets
Intangible Assets	- 0.94	Common Stock Total Equity
Intangible Assets	- 0.94	Other Assets
Cash	- 0.93	Net Debt